Cerebral Small Vessel DiseasesPhase 2ETLAS2NCT05173896

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

A Phase 2 study testing Tadalafil 20 MG in people with Cerebral Small Vessel Diseases and Stroke, Ischemic, run by Christina Kruuse at 2 sites in Denmark.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

In a randomized controlled trial the feasibility and effect of three months treatment with daily tadalafil, on cerebral blood flow/reactivity and cognition, is investigated in patients with cerebral small vessel disease. Read more about this study

Who is it for?: Ages 50 years and older
Conditions the study is for: Cerebral Small Vessel Diseases, Stroke, Ischemic
What is being tested?: Tadalafil 20 MG
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 100 participants
Where: 2 sitesDenmark
Study dates: 31 May 2022to Dec 2029
Phase: Phase 2
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 50 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

MRI/computed tomography (CT) evidence of small vessel occlusion stroke(s)/lacunar stroke(s) (involving ≤2 cm in the acute phase and ≤1.5cm in the late phase) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
Clinical evidence of cerebral small vessel disease can be: a) small vessel occlusion stroke (lacunar stroke) syndrome with symptoms lasting > 24 hours, occurring < 5 years ago; OR b) transient ischemic attack (TIA) with symptoms lasting < 24 hours AND with MR-DWI imaging performed acutely showing small vessel occlusion stroke, occurring < 5 years ago; OR c) TIA with symptoms lasting < 24 hours AND no acute MRI-DWI lesion but MRI/CT evidence of CSVD with old small vessel occlusion stroke(s) (involving ≤1.5cm) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
Age ≥ 50 years.

Who cannot join

Known diagnosis of dementia, medically treated dementia, or under investigation for dementia
Pregnancy or nursing
Women of childbearing age not taking contraception
Known cortical infarction (> 1.5 cm maximum diameter)
Known carotid artery stenosis ≥ 50 % with Doppler ultrasound, CT angiography, or MRI angiography diagnosed within the last five years
Known carotid or vertebral dissection as a cause of stroke

Show all 25Show fewer

Stroke after carotid or heart surgery
Known hypercoagulable disease
Systolic BP < 90 and/or diastolic BP < 50
Known severe renal impairment (eGFR < 30ml/min)
Known severe hepatic impairment (Child-Pugh > B)
History of non-arthritic anterior ischemic optic neuropathy
Concomitant use of PDE5 inhibitors e.g. sildenafil, tadalafil, and vardenafil during trial period
Patients receiving nicorandil and nitrates e.g. isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate
History of acute myocardial infarction in the last three months before trial intervention
Body weight > 130kg
Known cardiac failure (NYHA ≥ II)
Known persistent or paroxysmal atrial fibrillation/flutter
History of "sick sinus syndrome" or other supraventricular cardiac conduction conditions such as sinoatrial or atrioventricular block (2nd of 3rd degree)
Other known cardiogenic cause of stroke
Contraindication to CO2 challenge, eg severe respiratory disease
MRI not tolerated or contraindicated
Known monogenic causes of stroke i.e. CADASIL
Unable to provide informed consent
The participant does not wish to be informed about results from the MRI

Trial locations and contacts

2 sites in 1 country.

Denmark2 sites

Department of Neurology, Herlev Gentofte Hospital
Herlev, 2730
Danish Research Centre for Magnetic Resonance
Hvidovre, 2650

Other trials in Denmark

About this study

Read the detailed description

Cerebral small vessel disease is a progressive brain and blood vessel disease for which there currently is no effective treatment. The disease associates with 25 % of all stroke and 30 % of all dementia cases and imposes a major and increasing health burden worldwide. In this trial the investigator suggest a new promising solution to this problem.

Patients with cerebral small vessel disease, who experience stroke or vascular dementia, may show reduced brain perfusion or altered neurovascular reactivity. The investigator has previously shown that a single dose of tadalafil (20 mg), shortly increased blood supply to the brain in patients with cerebral small vessel disease. This holds promise for new effective treatment targets. The investigator test if patients find three months daily intake of tadalafil (20 mg) feasible, and if it alters cerebral perfusion, neurovascular reactivity, and cognition, including memory and planning ability. The trial will help identify new treatment targets to reduce the number of patients with stroke, stroke sequelae, and vascular dementia.

This trial is divided into one main study and three sub studies:

Main study
Dynamical MRI sub study
Cognitive sub study
Biomarker sub study

Conditions: Cerebral Small Vessel Diseases, Stroke, Ischemic
Being tested: Tadalafil 20 MG, Placebo
Medical subject headings: Cerebral Small Vessel Diseases, Ischemic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Tadalafil 20 MGDrug
Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
PlaceboDrug
Daily dose of oral over-encapsulated placebo tablets for three months.

Study groups in NCT05173896
Study group	Role	What they receive
Tadalafil	Experimental	Oral tadalafil (20 mg) capsules once daily for three months. Receives: Drug: Tadalafil 20 MG
Placebo	Placebo comparator	Oral placebo capsules once daily for three months. Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Feasibility of treatment defined as proportion of participants achieving full target dose of tadalafil/placebo.
Number of participants achieving full target dose of tadalafil/placebo by end of three months trial period. Outcome will be assessed by a structured questionnaire with tablet count.
Measured: From baseline to three months.

Secondary outcomes (37)

MRI - Cerebral Blood Flow
Change in cerebral blood flow measured with arterial spin labeling (ASL) during a sensory hand stimulus.
Measured: From baseline to three months.
MRI - Neurovascular reactivity and perfusion
Change in neurovascular reactivity, coupling, and cerebral blood flow/perfusion measured with BOLD/ASL during a visual stimulation with and without a carbon dioxide vascular challenge.
Measured: From baseline to three months.
MRI - Neurovascular reactivity
Change in neurovascular reactivity measured with blood-oxygen-level dependent (BOLD) during a sensory hand stimulus.
Measured: From baseline to three months.
MRI - Blood Brain Barrier
Change in blood brain barrier measured with diffusion-prepared (DP)-ASL MRI.
Measured: From baseline to three months.
MRI - STRIVE criteria
Relative changes (%) in STRIVE assessment, including new strokes, white matter hyperintensity, cerebral microbleeds, enlarged perivascular space, atrophy, and lacunes.
Measured: From baseline to three months.
Montreal Cognitive Assessment
Change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome.
Measured: From baseline to three months.
Symbol Digit Modalities Test
Change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome.
Measured: From baseline to three months.
Dementia Assessment by Rapid Test
Change in Dementia Assessment by Rapid Test - DART score. Score range 0-50. Higher scores mean a better outcome.
Measured: From baseline to three months.
Trail Making Test A
Change in time to perform Trail Making Test A. Quicker time means a better outcome.
Measured: From baseline to three months.
Trail Making Test B
Change in time to perform Trail Making Test B. Quicker time means a better outcome.
Measured: From baseline to three months.
Digit Span Forward
Change Digit Span Forward test score. Score range 0-16. Higher scores mean a better outcome.
Measured: From baseline to three months.
Digit Span Backward
Change Digit Span Backward test score. Score range 0-16. Higher scores mean a better outcome.
Measured: From baseline to three months.
Digit Span Arrangement
Change Digit Span Arrangement test score. Score range 0-16. Higher scores mean a better outcome.
Measured: From baseline to three months.
WAIS Letter Number Sequence
Change Letter Number sequence test score. Score range 0-30. Higher scores mean a better outcome.
Measured: From baseline to three months.
Word mobilising test - F, S, A, and animals
Change word mobilising test score. Higher scores mean a better outcome.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Spatial Working Memory
Change in spatial working memory score.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Motor Screening
Change in motor screening score.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Rapid Visual Information processing
Change in rapid visual information processing score.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning Task
Change in paired associates learning task score.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - One-Touch Stockings of Cambridge
Change in One-Touch Stockings of Cambridge score.
Measured: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Reaction Time
Change in reaction time score.
Measured: From baseline to three months.
Short Informant Questionnaire on Cognitive Decline in the Elderly - IQCODE
Change in short IQCODE score. Score range 1-5. A score of 3 means that the subject is rated on average as 'no change'.
Measured: From baseline to three months.
Becks Depression Inventory - BDD
Change in BDD score. Score range 0-63. Higher score means increased risk of depression.
Measured: From baseline to three months.
Fatigue Severity Scale - FSS
Change in FSS score. Score range 0-7. Higher score means increased fatigue severity.
Measured: From baseline to three months.
WHO-5 Well-Beeing Index
Change in WHO-5 score. Score range 0-100. Higher score means better quality of life.
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: vascular cell adhesion molecule (VCAM-1)
Changes in vascular cell adhesion molecule (VCAM-1) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: intercellular adhesion molecule-1 (ICAM-1)
Changes in intercellular adhesion molecule-1 (ICAM-1) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: interleukin-6 (IL-6)
Changes in interleukin-6 (IL-6) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: tumour necrosis factor alpha (TNF-α)
Changes in tumour necrosis factor alpha (TNF-α) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: interleukin 1beta (IL-1β)
Changes in interleukin 1beta (IL-1β) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: E-selectin
Changes in E-selectin (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: vascular endothelial growth factor (VEGF)
Changes in vascular endothelial growth factor (VEGF) (unit pg/ml).
Measured: From baseline to three months.
Vascular- and inflammatory biomarkers: specific micro RNA
Changes in specific micro RNA associated to vascular disease.
Measured: From baseline to three months.
Death, ischemic and hemorrhagic event, and dementia
Difference in composite measure of death, any ischemic event, hemorrhagic event or dementia per patient registry after three and five years respectively from end of trial.
Measured: From baseline to five years.
Blood pressure
Change in both systolic and diastolic blood pressure (unit mmHg).
Measured: From baseline to three months.
Heart rate
Change in heart rate (unit beats per minute).
Measured: From baseline to three months.
Adverse events
Difference in adverse events between groups.
Measured: From baseline to three months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

31 May 2022Dec 2029

First posted30 Dec 2021
Study start31 May 2022
Primary completion23 Sep 2024
Study completionDec 2029 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (3)Papers the sponsor has linked to this study.
Other trials for Cerebral Small Vessel DiseasesStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 100 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05173896
Sponsor's protocol ID: H-20031301
Other IDs: 2020-002329-27
Acronym: ETLAS2
Status last verified: Feb 2024
First submitted: 16 Nov 2021
Last updated: 9 Dec 2024
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: IPD can be accessed upon reasonable request and after evaluation from the investigator.

Publications

Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Robbins TW, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study. Cereb Circ Cogn Behav. 2025 Nov 11;9:100520. doi: 10.1016/j.cccb.2025.100520. eCollection 2025.
PubMed 41332889
Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, Nielsen MKK, Rasmussen BS, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025 Oct;56(10):2846-2857. doi: 10.1161/STROKEAHA.125.051602. Epub 2025 Jul 28.
PubMed 40718899
Olmestig J, Mortensen KN, Fagerlund B, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): study protocol for a randomized controlled trial. Trials. 2024 Aug 29;25(1):570. doi: 10.1186/s13063-024-08402-4.
PubMed 39210472

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Task-Oriented Training Versus High-Intensity Gait Training in People With Chronic Stroke
Stroke, Hemiplegia
RecruitingPhase 3
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Fabry Disease
Not yet recruitingObservational study
Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
Ischemic Stroke, Acute, Blood Pressure Variability
RecruitingPhase 3
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Cerebral Small Vessel Disease, Ischemic Stroke
RecruitingObservational study
A Study of Patients With Fabry Disease (US Specific)
Fabry Disease

All Cerebral Small Vessel Diseases trials

Study at a glance

From the registry record, last updated by the sponsor on 9 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
ClinicalTrials.gov ID: NCT05173896
Acronym / sponsor ID: ETLAS2 / H-20031301
Conditions: Cerebral Small Vessel Diseases, Stroke, Ischemic
Phase: Phase 2
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 100 participants (estimated)
Lead sponsor: Christina KruuseUniversity, hospital or other
Collaborators: Danish Research Centre for Magnetic Resonance, Bispebjerg Hospital, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, The Novo Nordic Foundation, Nordsjaellands Hospital
Study start: 31 May 2022 (actual)
Primary completion: 23 Sep 2024 (actual)
Study completion: Dec 2029 (estimated)
First posted: 30 Dec 2021 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This trial is divided into one main study and three sub studies:

Main study
Dynamical MRI sub study
Cognitive sub study
Biomarker sub study

Study design

Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
Tadalafil	Experimental	Drug: Tadalafil 20 MGOral tadalafil (20 mg) capsules once daily for three months.
Placebo	Placebo comparator	Drug: PlaceboOral placebo capsules once daily for three months.

Who may qualify

Ages: 50 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

MRI/computed tomography (CT) evidence of small vessel occlusion stroke(s)/lacunar stroke(s) (involving ≤2 cm in the acute phase and ≤1.5cm in the late phase) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
Clinical evidence of cerebral small vessel disease can be: a) small vessel occlusion stroke (lacunar stroke) syndrome with symptoms lasting > 24 hours, occurring < 5 years ago; OR b) transient ischemic attack (TIA) with symptoms lasting < 24 hours AND with MR-DWI imaging performed acutely showing small vessel occlusion stroke, occurring < 5 years ago; OR c) TIA with symptoms lasting < 24 hours AND no acute MRI-DWI lesion but MRI/CT evidence of CSVD with old small vessel occlusion stroke(s) (involving ≤1.5cm) and/or confluent deep white matter hyperintensities (≥ grade 2 on Fazekas's scale).
Age ≥ 50 years.

Key exclusion criteria (25 listed)

Known diagnosis of dementia, medically treated dementia, or under investigation for dementia
Pregnancy or nursing
Women of childbearing age not taking contraception
Known cortical infarction (> 1.5 cm maximum diameter)
Known carotid artery stenosis ≥ 50 % with Doppler ultrasound, CT angiography, or MRI angiography diagnosed within the last five years

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Tadalafil 20 MGDaily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.	Drug	Tadalafil
PlaceboDaily dose of oral over-encapsulated placebo tablets for three months.	Drug	Placebo

Primary outcome

Feasibility of treatment defined as proportion of participants achieving full target dose of tadalafil/placebo.
Time frame: From baseline to three months.
Number of participants achieving full target dose of tadalafil/placebo by end of three months trial period. Outcome will be assessed by a structured questionnaire with tablet count.

37 secondary outcomes

MRI - Cerebral Blood Flow
Time frame: From baseline to three months.
MRI - Neurovascular reactivity and perfusion
Time frame: From baseline to three months.
MRI - Neurovascular reactivity
Time frame: From baseline to three months.
MRI - Blood Brain Barrier
Time frame: From baseline to three months.
MRI - STRIVE criteria
Time frame: From baseline to three months.
Montreal Cognitive Assessment
Time frame: From baseline to three months.
Symbol Digit Modalities Test
Time frame: From baseline to three months.
Dementia Assessment by Rapid Test
Time frame: From baseline to three months.
Trail Making Test A
Time frame: From baseline to three months.
Trail Making Test B
Time frame: From baseline to three months.
Digit Span Forward
Time frame: From baseline to three months.
Digit Span Backward
Time frame: From baseline to three months.
Digit Span Arrangement
Time frame: From baseline to three months.
WAIS Letter Number Sequence
Time frame: From baseline to three months.
Word mobilising test - F, S, A, and animals
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Spatial Working Memory
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Motor Screening
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Rapid Visual Information processing
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning Task
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - One-Touch Stockings of Cambridge
Time frame: From baseline to three months.
Cambridge Neuropsychological Test Automated Battery - Reaction Time
Time frame: From baseline to three months.
Short Informant Questionnaire on Cognitive Decline in the Elderly - IQCODE
Time frame: From baseline to three months.
Becks Depression Inventory - BDD
Time frame: From baseline to three months.
Fatigue Severity Scale - FSS
Time frame: From baseline to three months.
WHO-5 Well-Beeing Index
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: vascular cell adhesion molecule (VCAM-1)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: intercellular adhesion molecule-1 (ICAM-1)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: interleukin-6 (IL-6)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: tumour necrosis factor alpha (TNF-α)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: interleukin 1beta (IL-1β)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: E-selectin
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: vascular endothelial growth factor (VEGF)
Time frame: From baseline to three months.
Vascular- and inflammatory biomarkers: specific micro RNA
Time frame: From baseline to three months.
Death, ischemic and hemorrhagic event, and dementia
Time frame: From baseline to five years.
Blood pressure
Time frame: From baseline to three months.
Heart rate
Time frame: From baseline to three months.
Adverse events
Time frame: From baseline to three months.

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2024.
Derived from this study: PubMed 41332889Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Robbins TW, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study. Cereb Circ Cogn Behav. 2025 Nov 11;9:100520. doi: 10.1016/j.cccb.2025.100520. eCollection 2025.
Derived from this study: PubMed 40718899Olmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, Nielsen MKK, Rasmussen BS, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025 Oct;56(10):2846-2857. doi: 10.1161/STROKEAHA.125.051602. Epub 2025 Jul 28.
Derived from this study: PubMed 39210472Olmestig J, Mortensen KN, Fagerlund B, Naveed N, Nordling MM, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): study protocol for a randomized controlled trial. Trials. 2024 Aug 29;25(1):570. doi: 10.1186/s13063-024-08402-4.
Individual participant dataSharing planned: Yes. IPD can be accessed upon reasonable request and after evaluation from the investigator.

Related trials for Cerebral Small Vessel Diseases

Recruiting
Task-Oriented Training Versus High-Intensity Gait Training in People With Chronic Stroke
Stroke, Hemiplegia
RecruitingPhase 3
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Fabry Disease
Not yet recruitingObservational study
Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
Ischemic Stroke, Acute, Blood Pressure Variability
RecruitingPhase 3
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Cerebral Small Vessel Disease, Ischemic Stroke
RecruitingObservational study
A Study of Patients With Fabry Disease (US Specific)
Fabry Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Christina Kruuse, MD, Prof principal investigator

Herlev Gentofte Hospital, Department of Neurology

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tadalafil 20 MG in people with Cerebral Small Vessel Diseases and Stroke, Ischemic, run by Christina Kruuse at 2 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of treatment defined as proportion of participants achieving full target dose of tadalafil/placebo. (time frame: From baseline to three months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05173896, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2024.